Fig. 4.

Imatinib treatment of K562 cells reduces miR-130a and miR-130b expression. K562 cells were treated with 1 μM imatinib for 24, 48 and 72 h and the expression levels of miR-130a and miR-130b were compared with untreated K562 cells. Quantitative PCR for individual miRNAs were performed and expression was normalized to the endogenous control RNU48. (a) Western blotting showing the decrease in Bcr-Abl expression (i) and the corresponding increase in Ccn3 (ii) in K562 cells with 24, 48 and 72 h of imatinib treatment (b) Expression levels of miR-130a and (c) miR-130b following 24, 48 and 72 h of imatinib treatment of K562 cells. Data represent the mean fold reduction in miR-130a and miR-130b expression relative to the untreated K562 cells (n = 3). *, p < 0.05; **, p < 0.01; ***, p < 0.001